Definium Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Definium Therapeutics, Inc. (DFTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 493.97 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 393.07K shares, a 115.92% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 100.90K shares, a 33.59% increase year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 6.48K shares, a 36.48% decline year-over-year.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 264.06K shares, a 465.03% increase from fiscal 2024.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 46.73K shares, a 68.73% decline from fiscal 2023.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 149.45K shares, a 286.29% increase from fiscal 2022.
- Definium Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 38.69K shares, a 98.83% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 393.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 493.97K shares 10-Q · filed 2026-08-06 | 493.97K shares derived: sum of 3 quarters · filed 2026-08-06 | 500.46K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 100.90K shares 10-Q · filed 2026-05-07 | 100.90K shares derived: sum of 2 quarters · filed 2026-05-07 | 107.38K shares derived: sum of 3 quarters · filed 2026-05-07 | 289.43K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 6.48K shares derived: sum of 2 quarters · filed 2026-02-26 | 188.53K shares derived: sum of 3 quarters · filed 2026-02-26 | 264.06K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 6.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 188.53K shares derived: sum of 2 quarters · filed 2025-11-06 | 264.06K shares 10-Q · filed 2025-11-06 | 283.18K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 182.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 257.57K shares 10-Q · filed 2025-07-31 | 276.70K shares derived: sum of 3 quarters · filed 2025-07-31 | 286.91K shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 75.53K shares 10-Q · filed 2025-05-08 | 94.66K shares derived: sum of 2 quarters · filed 2025-05-08 | 104.86K shares derived: sum of 3 quarters · filed 2025-05-08 | 119.85K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 19.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 29.33K shares derived: sum of 2 quarters · filed 2025-03-06 | 44.32K shares derived: sum of 3 quarters · filed 2025-03-06 | 46.73K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 10.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 25.19K shares derived: sum of 2 quarters · filed 2024-11-07 | 27.61K shares 10-Q · filed 2024-11-07 | 77.61K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 14.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 17.40K shares 10-Q · filed 2024-08-13 | 67.40K shares derived: sum of 3 quarters · filed 2024-08-13 | 110.36K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 2.42K shares 10-Q · filed 2024-05-08 | 52.41K shares derived: sum of 2 quarters · filed 2024-05-08 | 95.37K shares derived: sum of 3 quarters · filed 2024-05-08 | 95.37K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 92.96K shares derived: sum of 2 quarters · filed 2024-02-28 | 92.96K shares derived: sum of 3 quarters · filed 2024-02-28 | 149.45K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 42.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 42.96K shares derived: sum of 2 quarters · filed 2023-11-02 | 99.45K shares 10-Q · filed 2023-11-02 | 88.74K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | -2.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 56.50K shares 10-Q · filed 2023-08-03 | 45.78K shares derived: sum of 3 quarters · filed 2023-08-03 | -618.48K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 56.50K shares 10-Q · filed 2023-05-04 | 45.78K shares derived: sum of 2 quarters · filed 2023-05-04 | -618.48K shares derived: sum of 3 quarters · filed 2023-05-04 | -512.79K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | -10.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -674.98K shares derived: sum of 2 quarters · filed 2023-03-09 | -569.29K shares derived: sum of 3 quarters · filed 2023-03-09 | 38.69K shares 10-K · filed 2023-03-09 |
| 2022-09-30 | -664.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -558.57K shares derived: sum of 2 quarters · filed 2022-11-10 | 49.41K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 105.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 713.67K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 607.98K shares 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | 3.30M shares 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |